Iressa Use Should Not Be Limited By EGFR Mutation Testing, Researchers Say
Executive Summary
Data suggesting that the efficacy of Iressa is associated with an EGFR gene mutation should not stem use of anti-EGFR agents in mutation-negative patients, researchers said
You may also be interested in...
Iressa Access Program Might Answer Efficacy Questions, Researchers Say
AstraZeneca's database from the Iressa expanded access program could confirm whether patients with an EGFR mutation are more likely to benefit from therapy, researchers said
Iressa Access Program Might Answer Efficacy Questions, Researchers Say
AstraZeneca's database from the Iressa expanded access program could confirm whether patients with an EGFR mutation are more likely to benefit from therapy, researchers said
Genentech/OSI Tarceva Shows Two-Month Survival Improvement Over Placebo
Genentech/OSI's anti-EGFR agent Tarceva is associated with a two-month improvement in survival for refractory non-small cell lung cancer patients, according to pivotal trial data presented at the American Society of Clinical Oncology annual meeting in New Orleans June 7